4od3

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 2: Line 2:
<StructureSection load='4od3' size='340' side='right' caption='[[4od3]], [[Resolution|resolution]] 2.62&Aring;' scene=''>
<StructureSection load='4od3' size='340' side='right' caption='[[4od3]], [[Resolution|resolution]] 2.62&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[4od3]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OD3 OCA]. <br>
+
<table><tr><td colspan='2'>[[4od3]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OD3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OD3 FirstGlance]. <br>
-
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene><br>
+
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-
<tr><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
+
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
-
<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ocr|4ocr]], [[4ocs|4ocs]], [[4ocw|4ocw]], [[4od1|4od1]], [[4odh|4odh]], [[4org|4org]]</td></tr>
+
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ocr|4ocr]], [[4ocs|4ocs]], [[4ocw|4ocw]], [[4od1|4od1]], [[4odh|4odh]], [[4org|4org]]</td></tr>
-
<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Glucokinase Glucokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.2 2.7.1.2] </span></td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4od3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4od3 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4od3 RCSB], [http://www.ebi.ac.uk/pdbsum/4od3 PDBsum]</span></td></tr>
-
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4od3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4od3 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4od3 RCSB], [http://www.ebi.ac.uk/pdbsum/4od3 PDBsum]</span></td></tr>
+
</table>
-
<table>
+
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 15: Line 14:
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.,Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Nisc Comparative Sequencing, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR Nature. 2014 Mar 2. doi: 10.1038/nature13036. PMID:24590074<ref>PMID:24590074</ref>
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.,Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Nisc Comparative Sequencing, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR Nature. 2014 Mar 2. doi: 10.1038/nature13036. PMID:24590074<ref>PMID:24590074</ref>
-
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
</div>
== References ==
== References ==
Line 22: Line 21:
</StructureSection>
</StructureSection>
[[Category: Human]]
[[Category: Human]]
-
[[Category: Doria-Rose, N A.]]
+
[[Category: Doria-Rose, N A]]
-
[[Category: Gorman, J.]]
+
[[Category: Gorman, J]]
-
[[Category: Kwong, P D.]]
+
[[Category: Kwong, P D]]
-
[[Category: Mascola, J R.]]
+
[[Category: Mascola, J R]]
-
[[Category: Moore, P L.]]
+
[[Category: Moore, P L]]
-
[[Category: Morris, L.]]
+
[[Category: Morris, L]]
-
[[Category: Schramm, C A.]]
+
[[Category: Schramm, C A]]
-
[[Category: Shapiro, L.]]
+
[[Category: Shapiro, L]]
[[Category: Cap256]]
[[Category: Cap256]]
[[Category: Fab]]
[[Category: Fab]]

Revision as of 09:00, 5 January 2015

Crystal structure of human Fab CAP256-VRC26.07, a potent V1V2-directed HIV-1 neutralizing antibody

4od3, resolution 2.62Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools